ISCT Industry Community One Year Report
Read the one year report for a full run down of ISCT Commercialization Committee activity from the first twelve months of the Industry Community.
Click here to view the two page report
ISCT White Paper
Over 25% of ISCT's membership and Annual Meeting attendees are comprised of industry partners with the remainder of our membership stemming from research principal investigators, laboratory, regulatory and clinical disciplines within cell therapy.
ISCT has the development experience and knowledge through its membership base to develop concensus on scientific standards and policy, and coordinate solutions to commercialization roadblocks to significantly advance the field of regenerative medicine.
ISCT’s New Vision for Industry Partnership
A Changing Time: ISCT Embraces Its Industry Members.
With recognition that ISCT was uniquely positioned to serve the global translational regenerative medicine research community as a network hub for scientific standards and policy, the ISCT commissioned the establishment of an Industry Task Force (ITF) to address current and future roles for industry in March 2010.The ITF was composed of professionals participating in commercialization efforts with emphasis on international participation and was designed to include the spectrum of stakeholders in both the private and public setting.
ISCT invites you read the recommendations from the ITF now published in the journal Cytotherapy on how ISCT will pursue a greater strategic alignment with its industry members.
Since the society officially adopted these recommendations in May 2010, the newly re-chartered ISCT Commercialization Committee has met many of its key benchmarks for 2010 including the highly successfully launch of the new Industry Community with the participation of major pharma and healthcare companies and the launch of a series of commercial development focus groups to provide commercialization insight to drive key development decisions.
The NEW ISCT Industry Community
ISCT has launched a sponsorship based participation network for industry to:
- Replace traditional ISCT corporate membership with a more valuable peer to peer industry network.
- Offers access to Key Opinion Leaders (KOLs) in cell therapy translation including regulatory, scientific, process development and clinical experts.
- Drive priorities on the development of resources and initiatives to remove key obstacles to commercialization.
Click here for further information on the Industry Community.